Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ptc Therapeutics (NQ: PTCT )

42.89 +0.93 (+2.22%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ptc Therapeutics

< Previous 1 2 3 4 5 6 Next >
The Latest Analyst Ratings for PTC Therapeutics
Via Benzinga
PTC Therapeutics's Return On Capital Employed Insights
Via Benzinga
Why did Sarepta Therapeutics Stock Plummet?
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating. 
Via MarketBeat
Exposures Product Safety
Earnings Outlook For PTC Therapeutics
Via Benzinga
Expert Ratings for PTC Therapeutics
Via Benzinga
7 Nasdaq Stocks to Sell Before They Plunge in 2023
While loyalty may be a positive trait in most circumstances, when it comes to Nasdaq stocks to sell, you got to look out for number one. 
Via InvestorPlace
PTC Therapeutics Gets $1B Funding From Blackstone, Shares Fall
Via Benzinga
Reaction Is Overdone For PTC Therapeutics Pausing Huntington Trial Enrollment, Analyst Says
Via Benzinga
PTC Therapeutics Pauses Enrollment In Huntington's Candidate Trial In US
Via Benzinga
What 5 Analyst Ratings Have To Say About PTC Therapeutics
Within the last quarter, PTC Therapeutics (NASDAQ:PTCT) has observed the following analyst ratings: 
Via Benzinga
Earnings Scheduled For April 27, 2023
Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is expected to report earnings for its first quarter. 
Via Benzinga
Analyst Expectations for PTC Therapeutics's Future
Via Benzinga
Where PTC Therapeutics Stands With Analysts
Via Benzinga
Looking Into PTC Therapeutics's Return On Capital Employed
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
Via Benzinga
PTC Therapeutics's Return On Capital Employed Overview
According to Benzinga Pro data, during Q3, PTC Therapeutics (NASDAQ:PTCT) posted sales of $217.13 million. Earnings were up 28.12%, but PTC Therapeutics still reported an overall loss of $109.31... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Nuvalent (NASDAQ:NUVL) stock increased by 15.9% to $25.5 during Friday's pre-market session. The company's market cap stands at $1.2 billion. 
Via Benzinga
Expert Ratings for PTC Therapeutics
Analysts have provided the following ratings for PTC Therapeutics (NASDAQ:PTCT) within the last quarter: 
Via Benzinga
Analyst Ratings for PTC Therapeutics
Within the last quarter, PTC Therapeutics (NASDAQ:PTCT) has observed the following analyst ratings: 
Via Benzinga
Analyst Ratings for PTC Therapeutics
Analysts have provided the following ratings for PTC Therapeutics (NASDAQ:PTCT) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) jumped 153.9% to close at $3.30 on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 74.8% to $0.17 during Wednesday's pre-market session. The company's market cap stands at $14.1 million. 
Via Benzinga
Why Edwards Lifesciences Shares Are Trading Lower By Around 17%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) surged 179% to $3.6301. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Marten Transport, Silvergate Capital And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million. 
Via Benzinga
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.